;PMID: 12649279
;source_file_2997.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..45] = [t:0..45]
;1)section:[e:46..63] = [t:46..63]
;2)sentence:[e:68..200] = [t:68..200]
;3)section:[e:204..265] = [t:204..265]
;4)section:[e:269..369] = [t:269..369]
;5)sentence:[e:373..529] = [t:373..529]
;6)sentence:[e:530..624] = [t:530..624]
;7)sentence:[e:625..781] = [t:625..781]
;8)sentence:[e:782..873] = [t:782..873]
;9)sentence:[e:874..943] = [t:874..943]
;10)sentence:[e:944..1091] = [t:944..1091]
;11)sentence:[e:1092..1286] = [t:1092..1286]
;12)sentence:[e:1287..1524] = [t:1287..1524]
;13)section:[e:1528..1573] = [t:1528..1573]

;section 0 Span:0..45
;J Biol Chem.  2003 May 23;278(21):18997-9007.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Biol) (NNP:[7..11] Chem) (.:[11..12] .)
        (CD:[14..18] 2003) (NNP:[19..22] May) (CD:[23..25] 23) (::[25..26] ;)
        (CD:[26..29] 278) (-LRB-:[29..30] -LRB-) (CD:[30..32] 21)
        (-RRB-:[32..33] -RRB-) (::[33..34] :) (CD:[34..44] 18997-9007)
        (.:[44..45] .)))

;section 1 Span:46..63
;Epub 2003 Mar 20.
(SEC
  (FRAG (NNP:[46..50] Epub) (CD:[51..55] 2003) (NNP:[56..59] Mar)
        (CD:[60..62] 20) (.:[62..63] .)))

;sentence 2 Span:68..200
;Mutations in tau gene exon 10 associated with FTDP-17 alter the activity of
;an  exonic splicing enhancer to interact with Tra2 beta.
;[68..77]:variation-event:"Mutations"
;[81..84]:gene-rna:"tau"
;[90..97]:variation-location:"exon 10"
;[114..121]:gene-protein:"FTDP-17"
;[190..199]:gene-protein:"Tra2 beta"
(SENT
  (S-HLN
    (NP-SBJ
      (NP (NNS:[68..77] Mutations))
      (PP-LOC (IN:[78..80] in)
        (NP
          (NP
            (NML (SYM:[81..84] tau) (NN:[85..89] gene))
             (NN:[90..94] exon) (CD:[95..97] 10))
          (VP (VBN:[98..108] associated)
            (NP (-NONE-:[108..108] *))
            (PP-CLR (IN:[109..113] with)
              (NP (NN:[114..121] FTDP-17)))))))
    (VP (VBP:[122..127] alter)
      (NP
        (NP (DT:[128..131] the) (NN:[132..140] activity))
        (PP (IN:[141..143] of)
          (NP (DT:[144..146] an) (JJ:[148..154] exonic) (NN:[155..163] splicing)
              (NN:[164..172] enhancer))))
      (S-ADV
        (NP-SBJ (-NONE-:[172..172] *))
        (VP (TO:[173..175] to)
          (VP (VB:[176..184] interact)
            (PP (IN:[185..189] with)
              (NP (NN:[190..194] Tra2) (SYM:[195..199] beta)))))))
    (.:[199..200] .)))

;section 3 Span:204..265
;Jiang Z, Tang H, Havlioglu N, Zhang X, Stamm S, Yan R, Wu JY.
(SEC
  (FRAG (NNP:[204..209] Jiang) (NNP:[210..211] Z) (,:[211..212] ,)
        (NNP:[213..217] Tang) (NNP:[218..219] H) (,:[219..220] ,)
        (NNP:[221..230] Havlioglu) (NNP:[231..232] N) (,:[232..233] ,)
        (NNP:[234..239] Zhang) (NNP:[240..241] X) (,:[241..242] ,)
        (NNP:[243..248] Stamm) (NNP:[249..250] S) (,:[250..251] ,)
        (NNP:[252..255] Yan) (NNP:[256..257] R) (,:[257..258] ,)
        (NNP:[259..261] Wu) (NNP:[262..264] JY) (.:[264..265] .)))

;section 4 Span:269..369
;Department of Pediatrics, Washington University School of Medicine, St.
;Louis,  Missouri 63110, USA.
(SEC
  (FRAG (NNP:[269..279] Department) (IN:[280..282] of)
        (NNP:[283..293] Pediatrics) (,:[293..294] ,) (NNP:[295..305] Washington)
        (NNP:[306..316] University) (NNP:[317..323] School) (IN:[324..326] of)
        (NNP:[327..335] Medicine) (,:[335..336] ,) (NNP:[337..340] St.)
        (NNP:[341..346] Louis) (,:[346..347] ,) (NNP:[349..357] Missouri)
        (CD:[358..363] 63110) (,:[363..364] ,) (NNP:[365..368] USA)
        (.:[368..369] .)))

;sentence 5 Span:373..529
;Mutations in the human tau gene leading to aberrant splicing have been 
;identified in FTDP-17, an autosomal dominant hereditary neurodegenerative 
;disorder.
;[373..382]:variation-event:"Mutations"
;[396..399]:gene-rna:"tau"
;[459..466]:gene-protein:"FTDP-17"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (NNS:[373..382] Mutations))
        (PP-LOC (IN:[383..385] in)
          (NP (DT:[386..389] the) (JJ:[390..395] human) (SYM:[396..399] tau)
              (NN:[400..404] gene))))
      (VP (VBG:[405..412] leading)
        (PP-CLR (TO:[413..415] to)
          (NP (JJ:[416..424] aberrant) (NN:[425..433] splicing)))))
    (VP (VBP:[434..438] have)
      (VP (VBN:[439..443] been)
        (VP (VBN:[445..455] identified)
          (NP-1 (-NONE-:[455..455] *))
          (PP (IN:[456..458] in)
            (NP
              (NP (NN:[459..466] FTDP-17))
              (,:[466..467] ,)
              (NP (DT:[468..470] an)
                (ADJP (JJ:[471..480] autosomal) (JJ:[481..489] dominant))
                (JJ:[490..500] hereditary) (JJ:[501..518] neurodegenerative)
                 (NN:[520..528] disorder)))))))
    (.:[528..529] .)))

;sentence 6 Span:530..624
;Molecular mechanisms by which such mutations cause tau aberrant  splicing
;were not understood.
;[581..584]:gene-rna:"tau"
(SENT
  (S
    (SBAR-NOM-SBJ-2
      (WHNP-1
        (NP (JJ:[530..539] Molecular) (NNS:[540..550] mechanisms))
        (WHPP (IN:[551..553] by)
          (WHNP (WDT:[554..559] which))))
      (S
        (NP-SBJ (JJ:[560..564] such) (NNS:[565..574] mutations))
        (VP (VBP:[575..580] cause)
          (NP (SYM:[581..584] tau) (JJ:[585..593] aberrant)
              (NN:[595..603] splicing))
          (NP-MNR-1 (-NONE-:[603..603] *T*)))))
    (VP (VBD:[604..608] were) (RB:[609..612] not)
      (VP (VBN:[613..623] understood)
        (SBAR-NOM-SBJ-2 (-NONE-:[623..623] *T*))))
    (.:[623..624] .)))

;sentence 7 Span:625..781
;We characterized two mutations in exon 10 of the  tau gene, N279K and
;Del280K. Our results revealed an exonic splicing enhancer  element located in
;exon 10.
;[646..655]:variation-event:"mutations"
;[659..666]:variation-location:"exon 10"
;[675..678]:gene-rna:"tau"
;[685..686]:variation-state-original:"N"
;[686..689]:variation-location:"279"
;[689..690]:variation-state-altered:"K"
;[695..698]:variation-type:"Del"
;[698..701]:variation-location:"280"
;[701..702]:variation-state-generic:"K"
;[773..780]:variation-location:"exon 10"
(SENT
  (S
    (NP-SBJ (PRP:[625..627] We))
    (VP (VBD:[628..641] characterized)
      (NP
        (NP
          (NP (CD:[642..645] two) (NNS:[646..655] mutations))
          (PP-LOC (IN:[656..658] in)
            (NP
              (NP (NN:[659..663] exon) (CD:[664..666] 10))
              (PP (IN:[667..669] of)
                (NP (DT:[670..673] the) (SYM:[675..678] tau)
                    (NN:[679..683] gene))))))
        (,:[683..684] ,)
        (NP
          (NP (NN:[685..686] N) (CD:[686..689] 279) (NN:[689..690] K))
          (CC:[691..694] and)
          (NP (NN:[695..698] Del) (CD:[698..701] 280) (NN:[701..702] K)))))
    (.:[702..703] .))
  (S
    (NP-SBJ (PRP$:[704..707] Our) (NNS:[708..715] results))
    (VP (VBD:[716..724] revealed)
      (NP
        (NP (DT:[725..727] an)
          (NML (JJ:[728..734] exonic) (NN:[735..743] splicing))
          (NN:[744..752] enhancer) (NN:[754..761] element))
        (VP (VBN:[762..769] located)
          (NP (-NONE-:[769..769] *))
          (PP-LOC (IN:[770..772] in)
            (NP (NN:[773..777] exon) (CD:[778..780] 10))))))
    (.:[780..781] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[625..781]::S:S:

;sentence 8 Span:782..873
;The activity of this AG-rich splicing enhancer was  altered by N279K and
;Del280K mutations.
;[845..846]:variation-state-original:"N"
;[846..849]:variation-location:"279"
;[849..850]:variation-state-altered:"K"
;[855..858]:variation-type:"Del"
;[858..861]:variation-location:"280"
;[861..862]:variation-state-generic:"K"
;[863..872]:variation-event:"mutations"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[782..785] The) (NN:[786..794] activity))
      (PP (IN:[795..797] of)
        (NP (DT:[798..802] this)
          (ADJP (NN:[803..805] AG) (HYPH:[805..806] -) (JJ:[806..810] rich))
          (NN:[811..819] splicing) (NN:[820..828] enhancer))))
    (VP (VBD:[829..832] was)
      (VP (VBN:[834..841] altered)
        (NP-2 (-NONE-:[841..841] *))
        (PP (IN:[842..844] by)
          (NP-LGS
            (NP
              (NML (NN:[845..846] N) (CD:[846..849] 279) (NN:[849..850] K))
              (NML-1 (-NONE-:[850..850] *P*)))
            (CC:[851..854] and)
            (NP
              (NML (NN:[855..858] Del) (CD:[858..861] 280) (NN:[861..862] K))
              (NML-1 (NNS:[863..872] mutations)))))))
    (.:[872..873] .)))

;sentence 9 Span:874..943
;This exonic enhancer element interacts  with human Tra2 beta protein.
;[925..934]:gene-protein:"Tra2 beta"
(SENT
  (S
    (NP-SBJ (DT:[874..878] This) (JJ:[879..885] exonic) (NN:[886..894] enhancer)
            (NN:[895..902] element))
    (VP (VBZ:[903..912] interacts)
      (PP-CLR (IN:[914..918] with)
        (NP (JJ:[919..924] human)
           (NN:[925..929] Tra2) (SYM:[930..934] beta)
          (NN:[935..942] protein))))
    (.:[942..943] .)))

;sentence 10 Span:944..1091
;The interaction between Tra2 beta and the exonic  splicing enhancer
;correlates with the activity of this enhancer element in  stimulating
;splicing.
;[968..977]:gene-protein:"Tra2 beta"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[944..947] The) (NN:[948..959] interaction))
      (PP (IN:[960..967] between)
        (NP
          (NP (NN:[968..972] Tra2) (SYM:[973..977] beta))
          (CC:[978..981] and)
          (NP (DT:[982..985] the)
            (NML (JJ:[986..992] exonic) (NN:[994..1002] splicing))
            (NN:[1003..1011] enhancer)))))
    (VP (VBZ:[1012..1022] correlates)
      (PP-CLR (IN:[1023..1027] with)
        (NP
          (NP (DT:[1028..1031] the) (NN:[1032..1040] activity))
          (PP (IN:[1041..1043] of)
            (NP (DT:[1044..1048] this) (NN:[1049..1057] enhancer)
                (NN:[1058..1065] element)))
          (PP (IN:[1066..1068] in)
            (NP (VBG:[1070..1081] stimulating) (NN:[1082..1090] splicing))))))
    (.:[1090..1091] .)))

;sentence 11 Span:1092..1286
;Biochemical studies including in vitro splicing and RNA  interference
;experiments in transfected cells support a role for Tra2 beta  protein in
;regulating alternative splicing of human tau gene.
;[1214..1223]:gene-protein:"Tra2 beta"
;[1277..1280]:gene-rna:"tau"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1092..1103] Biochemical) (NNS:[1104..1111] studies))
      (VP (VBG:[1112..1121] including)
        (NP
          (NP
            (NP
              (ADJP (FW:[1122..1124] in) (FW:[1125..1130] vitro))
              (NN:[1131..1139] splicing)
              (NML-1 (-NONE-:[1139..1139] *P*)))
            (CC:[1140..1143] and)
            (NP (NN:[1144..1147] RNA) (NN:[1149..1161] interference)
              (NML-1 (NNS:[1162..1173] experiments))))
          (PP-LOC (IN:[1174..1176] in)
            (NP (VBN:[1177..1188] transfected) (NNS:[1189..1194] cells))))))
    (VP (VBP:[1195..1202] support)
      (NP (DT:[1203..1204] a) (NN:[1205..1209] role))
      (PP (IN:[1210..1213] for)
        (NP
           (NN:[1214..1218] Tra2) (SYM:[1219..1223] beta)
          (NN:[1225..1232] protein)))
      (PP (IN:[1233..1235] in)
        (S-NOM
          (NP-SBJ (-NONE-:[1235..1235] *))
          (VP (VBG:[1236..1246] regulating)
            (NP
              (NP (JJ:[1247..1258] alternative) (NN:[1259..1267] splicing))
              (PP (IN:[1268..1270] of)
                (NP (JJ:[1271..1276] human) (SYM:[1277..1280] tau)
                    (NN:[1281..1285] gene))))))))
    (.:[1285..1286] .)))

;sentence 12 Span:1287..1524
;Our results  implicate the human tau gene as a target gene for the
;alternative splicing  regulator Tra2 beta, suggesting that Tra2 beta may play
;a role in aberrant tau  exon 10 alternative splicing and in the pathogenesis
;of tauopathies.
;[1320..1323]:gene-rna:"tau"
;[1386..1395]:gene-protein:"Tra2 beta"
;[1413..1422]:gene-protein:"Tra2 beta"
;[1451..1454]:gene-rna:"tau"
;[1456..1463]:variation-location:"exon 10"
(SENT
  (S
    (NP-SBJ (PRP$:[1287..1290] Our) (NNS:[1291..1298] results))
    (VP (VBP:[1300..1309] implicate)
      (NP (DT:[1310..1313] the) (JJ:[1314..1319] human) (SYM:[1320..1323] tau)
          (NN:[1324..1328] gene))
      (PP (IN:[1329..1331] as)
        (NP
          (NP (DT:[1332..1333] a) (NN:[1334..1340] target)
              (NN:[1341..1345] gene))
          (PP (IN:[1346..1349] for)
            (NP
              (NP (DT:[1350..1353] the) (JJ:[1354..1365] alternative)
                  (NN:[1366..1374] splicing) (NN:[1376..1385] regulator))
              (NP (NN:[1386..1390] Tra2) (SYM:[1391..1395] beta))))))
      (,:[1395..1396] ,)
      (S-ADV
        (NP-SBJ (-NONE-:[1396..1396] *))
        (VP (VBG:[1397..1407] suggesting)
          (SBAR (IN:[1408..1412] that)
            (S
              (NP-SBJ (NN:[1413..1417] Tra2) (SYM:[1418..1422] beta))
              (VP (MD:[1423..1426] may)
                (VP (VB:[1427..1431] play)
                  (NP (DT:[1432..1433] a) (NN:[1434..1438] role))
                  (PP
                    (PP (IN:[1439..1441] in)
                      (NP (JJ:[1442..1450] aberrant)
                        (NML (SYM:[1451..1454] tau)
                           (NN:[1456..1460] exon) (CD:[1461..1463] 10))
                        (JJ:[1464..1475] alternative) (NN:[1476..1484] splicing)))
                    (CC:[1485..1488] and)
                    (PP (IN:[1489..1491] in)
                      (NP
                        (NP (DT:[1492..1495] the) (NN:[1496..1508] pathogenesis))
                        (PP (IN:[1509..1511] of)
                          (NP (NNS:[1512..1523] tauopathies)))))))))))))
    (.:[1523..1524] .)))

;section 13 Span:1528..1573
;PMID: 12649279 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1528..1532] PMID) (::[1532..1533] :) (CD:[1534..1542] 12649279)
        (NN:[1543..1544] -LSB-) (NNP:[1544..1550] PubMed) (::[1551..1552] -)
        (NN:[1553..1560] indexed) (IN:[1561..1564] for)
        (NNP:[1565..1572] MEDLINE) (-RRB-:[1572..1573] -RSB-)))
